SCHEMBL6717430

SCHEMBL6717430

Cc1ccccc1NC(=O)C(C)NC(=S)Nc1ccccc1[N+](=O)[O-]

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.59
▸ MEN1 O00255 4/20 0.59
▸ KMT2A Q03164 4/20 0.59
▸ LMNA P02545 2/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ MAPT P10636 4/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ MAPK1 P28482 2/20 0.47
▸ PGR P06401 1/20 0.47
▸ SCN1A P35498 1/20 0.47
▸ SCN2A Q99250 1/20 0.47
▸ SCN3A Q9NY46 1/20 0.47
▸ HTT P42858 1/20 0.46
▸ GRIN2D O15399 1/20 0.46
▸ GRIN3B O60391 1/20 0.46
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2A Q12879 1/20 0.46
▸ GRIN2B Q13224 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713938 0.88 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6723929 0.88 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6716851 0.88 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6716241 0.85 SMN1; SMN2 (0.55) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6716834 0.85 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6713812 0.85 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6723395 0.82 ALDH1A1 (0.53) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6717473 0.82 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6723568 0.81 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6723186 0.81 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 — — US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885MEN1 2933/4885KMT2A 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback